Wednesday, September 8th

10:30-10:35  OPEN AND WELCOME: DR TRACY KING

10:35-11:05  CLINICAL TREATMENT UPDATES
Session Chairs: Dr Tracy King & Harald Titzer

10:35-11:05  Keynote: The impact of Covid-19 on myeloma
Prof Heinz Ludwig, MD

11:05-11:35  Nursing implications of CAR-T and Bi-specific antibody therapies
Donna Catamero, ANP-BC, OCN, CCRC

11:35-12:05  The evolving symptom burden in myeloma: Coaching resilience and persistence
Dr Sandra Kurtin, PhD, ANP-C, AOCN

12:05-12:30  Q&A and Panel Discussion

12:30-13:30  EXPOSITION AND BREAK

13:30-15:00  ORAL ABSTRACT SESSION
Session Chairs: Monica Morris & Dr Tiffany Richards

Higher EQ-5D-5L utility scores at diagnosis are associated with improved overall survival in Australian patients with multiple myeloma: results from the ANZ Myeloma and Related Diseases Registry
Elizabeth Moore, PhD

The Importance of Regular Disease Monitoring for Patients with Low or Low Intermediate Risk Monoclonal Gammopathy of Undetermined Significance (MGUS)
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN

Adapting and improving a Myeloma Support group during the pandemic
Emma Dowling

Lessons learned: Patient management and outcomes of Multiple Myeloma patients during the COVID-19 pandemic in New York City
Donna D. Catamero, ANP-BC
Introducing frailty assessment into a myeloma service – a Quality Improvement Project (QIP)
Catherine Morrow, RN, BSc

Project to Improve Volume of Treatment and Satisfaction-PIVOTS, A Quality Improvement Project
Mary Steinbach, DNP, APRN

15:00-15:30  EXPOSITION AND BREAK

OPTIMISING SUPPORTIVE CARE
Session Chairs: Dr Beth Faiman and Matthias Hellberg-Naegele

15:30-16:00  Measuring the impact of myeloma: HRQoL and patient experiences
Dr Tracy King, PhD, MN(Lead), RN

16:00-16:30  Disparities in Myeloma: Closing the gap
Dr Joseph Mikhael, MD, Med, FRCPC, FACP

16:30-16:45  Q&A and Panel Discussion

16:45-16:50  CLOSING REMARKS: DR BETH FAIMAN